Sarcoidosis: Pulmonary and Skin Studies Before and After ACTH and Cortisone Therapy

¹ Research Fellow in Medicine, Tufts University School of Medicine, Chief Resident, Department of Inhalation Therapy, The Boston City Hospital., Suburban Cook County Tuberculosis Sanatorium District, Hinsdale, Illinois.
² professor and Chairman, Department of Dermatology and Syphilology, Tufts University School of Medicine, Physician-in-Chief for Diseases of the Skin, The Boston City Hospital.
³ Resident, Department of Diseases of the Skin, The Boston City Hospital, Teaching Assistant, Department of Dermatology and Syphilology, Tufts University School of Medicine.
⁴ Assistant in Medicine, Tufts University School of Medicine.
⁵ Clinical Professor of Medicine, Tufts University School of Medicine, Director, Department of Inhalation Therapy and the Lung Station (Tufts), The Boston City Hospital.

1. Sarcoidosis, when encountered in any of its special forms, should be studied for evidence of pulmonary involvement, as well as for other systemic manifestations.

2. Adrenocorticosteroid therapy, when surrounded by the proper safeguards of complete laboratory controls and careful clinical observations, may be safely used over a period of time of from four to six weeks (possibly longer), to initiate resolution of the clinically active manifestations of sarcoidosis.

3. Pulmonary pathology of sarcoidosis responds more slowly to adrenocorticosteroid therapy, as measured by pulmonary function studies, and to a lesser degree than do skin and other visceral lesions.